More news about Aspivix

Aspivix raises over CHF 1.8M in Series-A financing

20.08.2018 16:21
Aspivix Mathieu Horras

Aspivix, the Swiss start-up innovating women’s care, focused on the development of non-traumatic and minimally invasive surgical instruments for gynecology, announces the successful closing of a Series-A financing round of over CHF 1'800'000.

Aspivix - Makers of non-traumatic and minimally invasive surgical instruments for gynecology - raises $2M in financing round.

This Series-A-round will be used to finalize the development and support the clinical trial, of Aspivix’s first product. This device is dedicated to allowing painless placement of Intra-uterine contraceptive devices and other gynecology procedures. Current procedures use forceps which cause pain in over 80% of women, and frequent bleedings. Aspivix uses a gentle suction technology and will fulfill a major medical need.

The round syndicate is made of 4FO (which led the financing), Zürcher Kantonalbank (ZKB) and several private investors from Business Angels Switzerland (BAS)

Besides bringing financial support, the Series-A investors add also valued vision and experience in the Life Science industry. “It is a great pleasure and privilege to welcome our new investors,” said Mathieu Horras, CEO and co-founder of Aspivix SA (picture above). “The proceeds will be used to accelerate the industrialization of Aspivix and to bring the product to the European market. The trust from investors is a great motivation for us to realize our vision in women’s care and make a difference for millions of women worldwide.”

“We are delighted to support this innovative company, which is another proof of the quality of the Swiss start-up ecosystem.  We have been impressed by the quality of the team, the product potential and the major benefits the company could bring to women world-wide. We will be looking forward to bringing this product to market in the shortest possible time.” says Jean-Pierre Rosat, General Partner of 4FO.

(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

More news about Aspivix
Please login or
register to use the
bookmark feature

Related News

Highlights Aspivix

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

 

Principal

22.03.2019
Editorial

Give the people what they want

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS